✔ COMPLIANT
★★★
Medical Equipment, Supplies & Distribution | USA
Business: PASS
Intersect Ent Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass all the three standards we check against.
FTSE
| Debt/A | 27.99% | ✔ |
| Cash/A | 5.95% | ✔ |
| (AR+C)/A | 12.58% | ✔ |
AAOIFI
| Debt/MC | 6.95% | ✔ |
| Cash/MC | 8.13% | ✔ |
DJIM
| Debt/24MC | 9.41% | ✔ |
| Cash/24MC | 2% | ✔ |
| AR/24MC | 2.23% | ✔ |
Total Analysts: 0
Recommendation Rating
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Low: 0
High: 28.3
| Market cap | 916180196 |
| Assets | 227381000 |
| Dividends per Share | |
| Revenue Growth | -26.2 |
Intersect ENT, Inc. is an ear, nose and throat medical technology provider. Its products are steroid releasing implants designed to treat patients suffering from chronic rhinosinusitis. Its products include the PROPEL family of products PROPEL, PROPEL Mini and PROPEL Contour, and the SINUVA, mometasone furoate Sinus Implant. The PROPEL family of products are used in conjunction with sinus surgery primarily in hospitals and ambulatory surgery centers, as well as used in the physician office setting of care in conjunction with balloon dilation and various post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, including the VENSURE sinus dilation platform and the CUBE surgical navigation system and instrumentation, which complements its PROPEL and SINUVA sinus implants.
| ✔ FTSE | ✔ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses